Last reviewed · How we verify
NCT00033475
Reduced Immunosuppressive Therapy With or Without Donor White Blood Cells in Treating Patients With Lymphoproliferative Disease After Organ Transplantation
Phase 3 trial testing therapeutic allogeneic lymphocytes in Lymphoproliferative Disorder in 50 participants. Completed.
Quick facts
| Lead sponsor | University of Edinburgh |
|---|---|
| Phase | Phase 3 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Primary purpose | treatment |
| Enrollment | 50 |
| Start date | 1 March 2001 |
| Sites | 12 locations across United Kingdom |
Drugs / interventions tested
- therapeutic allogeneic lymphocytes — full drug profile →
Conditions studied
- Lymphoproliferative Disorder — all drugs for Lymphoproliferative Disorder →
Sponsor
University of Edinburgh
Who can join
Adults 0 to 120, any sex, with Lymphoproliferative Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
RATIONALE: Some types of lymphoproliferative disease are associated with Epstein-Barr virus. Combining reduced immunosuppressive therapy with donor white blood cells that have been treated in the laboratory to kill cells infected with Epstein-Barr virus may be an effective treatment for lymphoproliferative disease. PURPOSE: Randomized phase III trial to compare the effectiveness of reducing immunosuppressive therapy with or without donor white blood cells in treating patients who have Epstein-Barr virus-associated lymphoproliferative disease after organ transplantation.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT00033475
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of therapeutic allogeneic lymphocytes
Trials testing the same drug.
- NCT00448201 — Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant · Phase 2 · completed
- NCT00056095 — Allogeneic Stem Cell Transplant in Treating Patients With Metastatic Kidney Cancer · Phase 2 · completed
- NCT00043979 — Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas · Phase 2 · completed
- NCT00053989 — NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/Disorders · Phase 2 · completed
- NCT00004878 — Donor Lymphocytes to Prevent Graft-Versus-Host Disease in Patients With Chronic Myeloid Leukemia · Phase 2 · withdrawn
Other recruiting trials for Lymphoproliferative Disorder
Currently open trials in the same condition.
- NCT06630104 — Understanding the Mechanisms of Clonal and Non-clonal Cytopenia Following CAR-T Therapy for Multiple Myeloma or CD19+ Ly · NA · recruiting
- NCT04883437 — Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgk · Phase 2 · recruiting
- NCT03258567 — Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas · Phase 2 · recruiting
- NCT02861417 — Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing · Phase 2 · active not recruiting
- NCT02402244 — Project: Every Child for Younger Patients With Cancer · recruiting
Other University of Edinburgh trials
Trials by the same sponsor.
- NCT07341126 — Use of a Novel Camera to Check the Bowel After Polyp or Tumour Removal · not yet recruiting
- NCT07523997 — Imaging of Endometriosis With Total-body PET-CT (PET-Endo) · not yet recruiting
- NCT07430540 — Optimising Colorectal Cancer Patient Pathways · NA · not yet recruiting
- NCT07430527 — Secondary Care Colorectal Cancer Pathway Review · not yet recruiting
- NCT07436026 — Latin America Network for Primary Palliative Care · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00033475 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Edinburgh
- Last refreshed: 15 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00033475.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing